There is little information available on the possible toxic effects that antiretroviral (ARV) drugs used for the treatment of human immunodeficiency virus (HIV)-infected subjects, may have on the central nervous system (CNS) resident cells. Moreover, it remains unclear whether the efficacy of the ARV drugs may also be due to their ability to exert extravirological effects on factors responsible for the development of HIV brain injury, e.g., matrix metalloproteinases (MMPs). This study investigates the toxicity of three different ARV drugs and on their ability to modulate levels and expression of gelatinases A (MMP-2) and B (MMP-9) in astrocytes. Primary cultures of rat astrocytes were activated by exposure to lipopolysaccaride (LPS) and simultaneously treated with darunavir, maraviroc, or raltegravir, used alone or in combination. Among the tested drugs, maraviroc was the less toxic for astrocytes. At toxic concentration (TC 50 ), the studied drugs induced the production of reactive oxygen species (ROS), suggesting that the oxidative stress may represent a mechanism of ARV toxicity. As assessed by gelatin zymography and RT-PCR, the single antiretroviral drugs reduced levels and expression of both MMP-2 and MMP-9 through the inhibition of the signaling transduction pathway of extracellular signal-regulated kinase1/2, which is involved in the regulation of MMP-9 gene. A synergistic inhibition of MMP-2 and MMP-9 was observed with combinations of the studied ARV drugs. The present results indicate that maraviroc, darunavir, and raltegravir, through their ability to inhibit MMP-2 and MMP-9 at doses non-toxic for astrocytes, might have a great potential for the management of HIV-associated neurological complications.
Human immunodeficiency virus (HIV-1) enters the CNS in the early stage of infection and frequently determines a spectrum of neurological symptoms known as HIV-associated neurocognitive disorders (Antinori et al. 2007) . The term encompasses a spectrum of disorders of the CNS progressively severe, ranging from asymptomatic or minor neurological disorders to the most severe form of HIVassociated dementia (HAD). The introduction of combination antiretroviral therapy (cART) has dramatically reduced the incidence of the severe forms of HIV-associated dementia (Sacktor et al. 2001 (Sacktor et al. , 2002 Saksena and Smit 2005) ; nevertheless mild-moderate neurocognitive manifestations still affect about 40% of HIV-positive subjects despite the suppression of plasma viremia (Clifford 2008; Nwogu et al. 2016) .
The explanation of the persistence of neurocognitive disorders may depend on several factors, including the development of concomitant opportunistic infections, the persistent state of inflammation/immune activation and a reduced efficacy of therapy in the CNS reservoir (Valcour et al. 2011) . In fact, the amount of drug that penetrates through the blood-brain barrier (BBB) is low and may be insufficient to inhibit viral replication in the HIV 'sanctuaries' (Nwogu et al. 2016) .
On the other hand, there is emerging evidence that high CNS concentration of some ARVs may exert neurotoxic effects that may be associated with the development of HIV-associated neurocognitive disorders. In this regard, some authors have demonstrated that the decision to discontinue antiretroviral therapy for up to 96 weeks in a group of immunologically and virologically stable HIV subjects resulted in improved cognitive functions (Robertson et al. 2010) . Therefore, the efforts to deliver higher concentrations of antiretroviral drugs to the CNS should balance the possible detrimental effects of these antiretroviral drugs. Unfortunately, little is known about the toxicity of these compounds within the CNS, and in particular on the CNS resident cells. Only an in vitro study has assessed the effect of 15 ARV drugs on primary cultures of rat neurons, showing a wide range of toxicities between the antiretrovirals, with some toxic concentrations overlapping those currently seen in plasma and cerebrospinal fluid (CSF) of HIV-positive individuals (Robertson et al. 2012) . However, no studies have investigated on the toxicity of ARVs on astrocytes and microglia, in which HIV actively replicates and therefore represent the targets of these drugs. The study of the underlying mechanisms responsible for the neurotoxicity of ARV drugs on glial cells represents an area of active investigation.
Clinically, the therapy for HIV-infected individuals consists in the simultaneous administration of two or three antiretroviral drugs, belonging at least to two different classes, which act at different stages of the replication cycle of the virus.
The benefits yielded by antiretroviral drugs are not limited to suppression of HIV burden but also to their ability to exert extravirologic effects on factors responsible for viral dissemination, tissue and neurological damage in course of HIV infection, such as matrix metalloproteinases (MMPs) (Liuzzi et al. 2000) . MMPs are a family of zinc-dependent endopeptidases responsible for the degradation of the components of the extracellular matrix (Woessner 1991) , which have been identified as important pathogenetic factors in various diseases associated with HIV infection, including neurological injury . It has been demonstrated that human monocytes infected in vitro with HIV or stimulated with the Tat protein of HIV are able to secrete high levels of gelatinase B (MMP-9) (Dhawan et al. 1992; Lafrenie et al. 1996) . Our research group has shown the presence of MMP-9 in the CSF of patients with HIV-related neurological manifestations (Liuzzi et al. 2000) , suggesting that this enzyme may represent an important target for a novel therapeutic approach, in particular for the treatment of HIV-related neurological disorders, for which currently there is not a specific therapy.
In our laboratory, we have demonstrated the ability of two antiretroviral drugs of first generation, zidovudine, a nucleoside reverse transcriptase inhibitor, and indinavir, a protease inhibitor, to inhibit in vitro the expression of MMP-2 and MMP-9 (Liuzzi et al. 2004a) in LPS-activated glial cells. We have also demonstrated the inhibition of MMP-9 in peripheral blood mononuclear cells of HIV-infected patients receiving antiretroviral therapy (Latronico et al. 2007) .
Based on these observations, the objective of our research was to study the effects of three ARV drugs belonging to the classes of integrase inhibitors (raltegravir), protease inhibitors (darunavir), and entry inhibitors (maraviroc), used alone or in combinations, in an in vitro system represented by LPSactivated rat astrocytes. In particular, we have detected the concentrations of ARV drugs that resulted to be toxic to astrocytes and we have investigated the extravirologic effects exerted by these drugs on the levels and expression of MMP-2 and MMP-9.
The results obtained from this study indicate that the investigated ARV drugs are not toxic to astrocytes at concentrations detected in CSF and serum of HIV patients under ARV therapy. In addition, this study highlighted the ability of the ARV drugs to inhibit MMP-2 and MMP-9 levels and expression with mechanisms that are independent from their antiviral activity.
Materials and methods

Chemicals
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin and streptomycin were provided by GIBCO (Paisley, Scotland). Gelatin, DNase 1, poly-L-lysine, trypsin, lipopolysaccharide (LPS), 1,10 phenanthroline (PA), Trypan Blue and 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) were purchased from Sigma (St. Louis, MO, USA 
Ethics statement
The experimental procedures involving animals were carried out in accordance with the recommendations in the NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of University of Bari, Italy (Permit Number: 23-98-A). All efforts were made to minimize the number of animals used and to ameliorate their suffering. For this study randomization and blinding were not performed. The study was not pre-registered.
Preparation of astrocyte cultures
Astrocytes were prepared from primary cell cultures of neocortical tissues from 1-day-old Wistar rats (Harlan Laboratories Srl, Udine, Italy) as described by Latronico et al. (2013a) . For the experiments of this work, we used 8 litters of 12 pups each of both sexes. The pups were from four female Wistar rats (RRID: RGD_737960) which were breeding and mated in the animal facility of the Department of Biosciences, Biotechnologies and Biopharmaceutics of University of Bari (Italy). No sample calculation was performed to predetermine the sample size. All animals were maintained at a room temperature of 22°C, humidity at 40-50%, on a 12 : 12 h light/dark cycle. Each pregnant dam was housed individually in clear plastic cages with free access to food and tap water. One day after birth the pups were removed from their dams, anesthetized with ether vapors, killed by rapid decapitation and then dissected neocortical tissues were used for the preparation of primary glial cell cultures. Briefly, rat brains, cleaned of meninges and blood vessels, were dissected and minced by passage through a stainless steel mesh (40 mesh) and incubated for 10 min at 37°C with 0.25% trypsin and 0.01% DNase in DMEM. After addition of 10% FBS, the cells were passed through a 100 mesh and cell viability was assessed by Trypan Blue dye exclusion. Cells were plated in poly-L-lysine-coated flasks (75 cm 2 ) at a density of 1.5 9 10 7 viable cells/flask in DMEM, 10% FBS, 100 U/mL penicillin, 100 lg/mL streptomycin, and maintained at 37°C in a 5% carbon dioxide CO 2 incubator with a change of medium twice a week. After 10 days in culture, oligodendrocytes and microglia were separated from astrocytes by mechanical dislodging. Astrocytes were then obtained by trypsinization (0.25% trypsin/0.02% EDTA) (McCarthy and De Vellis 1980) . Final purification of astrocytes from microglia and oligodendrocytes was obtained after three repetitions of re-plating and trypsinization. The purity of the final cell culture was assessed by immunostaining for GFAP. More than 98% of the cells were GFAPpositive in all the preparations.
Treatment of LPS-activated astrocytes with antiretroviral drugs
Confluent astrocytes, seeded in 96 well plates, were washed with serum-free DMEM, activated with 10 lg/mL of LPS and simultaneously treated with different concentrations of MVC, RAL or DRV in serum-free DMEM. Negative and positive controls were represented, respectively, from unstimulated and untreated astrocytes in serum-free DMEM and astrocytes stimulated with LPS. In addition, since the stock solutions of RAL (8.3 mM), MVC (9.7 mM) and DRV (6.7 mM) were made in dimethyl sulfoxide, a dose-response curve to dimethyl sulfoxide, diluted in culture medium at the same solvent concentration present in the ARV samples, was run to obtain a reliable estimation of ARV toxicity. The incubation was performed in a final volume of 100 lL of serum-free DMEM for 24 h at 37°C, 5% carbon dioxide. At the end of the incubation period, the medium was collected and centrifuged at 7359g, then cell culture supernatants stored at À20°C until use. The cells were lysed for RNA isolation or subjected to the test of cell viability by MTT.
MTT cell viability assay Cytotoxicity of antiretroviral drugs on astrocytes was detected using MTT assay (Mosmann 1983 ). This assay is based on the reduction, in viable cells, of MTT by the mitochondrial succinate dehydrogenase, with the formation of a blue formazan product, which can be measured spectrophotometrically. Briefly, after 24 h of treatment with the antiretroviral drugs, the culture medium was collected and cells were rinsed in phosphate-buffered saline and incubated at 37°C, 5% CO 2 for 2 h with 0.5 mg/mL MTT. Reaction was stopped by removing the medium and the formazan crystals in the cells were solubilized with absolute ethanol. The difference between the absorbance of each sample at 560 and 690 nm was measured by a VersaMaxMicroplate Reader (Molecular Devices, Sunnyvale, CA, USA). The value of the untreated sample (CTRL) was set at 100% and the cell viability was expressed as percentage of control using the following equation: % cell viability = (A560-A690 sample/ A560-A690 CTRL) 9 100.
The TC 50 , representing the dose of drug inducing 50% of cell mortality, was calculated for each individual drug using the GraphPad Prism 5.0 Software (GraphPad Software Inc., San Diego, CA, USA).
Reactive oxygen species detection
For the detection of intracellular free radicals of oxygen (ROS), confluent astrocytes (in 6-well plates) were loaded with 10 lM DCFH-DA in phenol red-free DMEM at 37°C for 30 min. Then, wells were washed twice with DMEM and treated for 1 h with the individual drugs at doses (lM) that matched the therapeutic concentrations detected in plasma and CSF of HIV-positive subjects as well as at the maximum non-toxic concentrations and at the TC 50 (see Table 1 ). Cells treated only with DCFH-DA represented the negative control (CTRL), whereas cells treated or with 100 lM of H 2 O 2 or with 10 lg/mL LPS represented the positive controls. After incubation, the culture medium was removed and cells were rinsed three times with phosphate-buffered saline. Cells were subjected to spectrofluorimetric analysis at 525 nm under excitation at 485 nm in a microplate reader (Cytation 3 Imaging Reader; Bio Tek, Winooski, VT, United States). Results were normalized to cell viability and ROS production was expressed as relative percentage of photoluminescence intensity (PLI) versus negative control (CTRL) using the following equation: % ROS production = (PLI sample /PLI CTRL ) 9 100.
Detection of gelatinases
Gelatinases in cell culture supernatants were detected by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis zymography according to the method of Heussen and Dowdle (1980) , as modified by Liuzzi et al. (2011) . Briefly, 50 lL of culture supernatant, corresponding to about 10 lg of total proteins, were supplemented with 30 lL of electrophoresis loading buffer containing SDS. Samples were then analyzed in a 7.5% polyacrylamide gel copolymerized with 0.1% (wt/v) gelatin. Stacking gels contained 5.4% polyacrylamide. The electrophoretic run was performed at 4°C for approximately 18 h at 80 V, then gels were washed twice for 20 min in 2.5% (wt/v) Triton X-100/10 mM CaCl 2 in 50 mM TrisHCl, pH 7.4 (washing buffer) followed by an incubation for 24 h at 37°C in 1% (wt/v) Triton X-100/50 mM Tris-HCl/10 mM CaCl 2 , pH 7.4 (developing buffer). The gels were stained with Coomassie brilliant blue R-250 and destained in methanol/acetic acid/H 2 O. Gelatinase activity was detected as a white band on a blue background and was quantified, after scanning densitometry, by computerized image analysis using the Image Master 1D program (Pharmacia Biotech, Uppsala, Sweden). Gelatinase activity was expressed as optical density (OD) 9 mm 2 , representing the scanning area under the curves which takes into account both brightness and width of the substrate lysis zone. Results were expressed as percentage of inhibition using the following equation: % inhibition = [100 À (OD sample /OD positive control ) 9 100].
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from astrocytes using the QiagenRNeasy mini kit according to the manufacturer's instructions. The concentration and purity of the isolated RNA were determined using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, United States). Complementary DNA (cDNA) was synthesized from 500 ng of RNA using the QuantiTect Reverse Transcription kit according to manifacturer's instructions. A total of 25 ng of reverse transcription products was used to amplify a 591 bp fragment using specific primers (sense 5 0 -GTCACTCCGCTGCGCTTTTCTCG-3 0 ; antisense 5 0 -GACA-CATGGGGCACCTTCTGA-3 0 ) for the rat MMP-2 sequence and a 541 bp fragment using specific primers (sense 5 0 -CGGAG-
Amplification of a 308 bp fragment of rat 18S rRNA (sense 5 0 -
, a relatively invariant internal reference RNA, was performed in parallel. The primer sets, already validated in other studies (Liuzzi et al. 2004a,b; Gramegna et al. 2011; Latronico et al. 2013b ) specifically recognize only the genes of interest as indicated by amplification of a single band of the expected size of the PCR products. To exclude a ceiling effect of amplification of the analyzed samples, preliminary experiments were performed to determine the PCR cycling conditions. According to the results obtained, 25 cycles of PCR were carried out, each one consisting of denaturation at 94°C, annealing at 59°C and extension at 72°C in a thermal cycler (PTC-100 Programmable Thermac Controller, MJ Research, Inc., Walthan, MA, USA). PCR products were analyzed in 1.5% agarose gels. Gels were then processed for densitometric analysis as described for protein gels.
After the densitometric analysis of gels, amplification of the target cDNAs were normalized to 18S rRNA expression, and results were expressed as percentage of inhibition as reported for gelatinase quantification.
Detection of ERK 1/2 phosphorylation by western blot analysis ERK 1/2 were detected by immunoblot analysis as reported in Latronico et al. (2013a) . Briefly, primary astrocytes plated in 6-well plates, made quiescent in serum-free medium for 24 h, were pretreated for 1 h with MVC, RAL and DRV at the highest non-toxic concentration, then activated for 2 h with 10 lg/mL of LPS. Unstimulated and untreated astrocytes or LPS-activated astrocytes represented the negative and positive controls, respectively. After the incubation period, cells were lysed with 20 mM Tris-HCl, 150 mM NaCl, 2.5 mM Na-pyrophosphate, 1 mM b-glycerophosphate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 20 lg/mL aprotinin, 1 mM EGTA, 1 mM Na-fluoride, 1 mM Na 3 VO 4 , pH 7.5. Cell lysates were centrifuged at 13 000 g for 10 min at 4°C, and protein concentration was determined using the Bradford assay. Equal amounts of lysates, corresponding to 60 lg of total proteins, were precipitated with 1 mL of cold acetone at À20°C for 1 h. After centrifugation, dry pellets were resuspended in SDS buffer and the samples were separated using 10% SDSpolyacrylamide gel electrophoresis. Proteins were then immunoblotted onto polyvinylidene difluoride membranes. After blocking overnight at 4°C with 0.05% Tween 20, 1% milk, 1% bovine serum albumin in 150 mMNaCl, 20 mMTris-HCl (Tris-buffered saline) (pH 7.5), blots were probed overnight at 4°C with a monoclonal anti-p-ERK 1/2 antibody (1 : 500). The blots were washed three times with 0.05% Tween 20 in Tris-buffered saline then the membranes were probed with anti-mouse-horseradish peroxidase secondary antibody (1 : 20 000) for 2-h at 24°C and detected with enhanced chemiluminescence. After exposure to autoradiographic films, membranes were stripped and incubated with an antibody specific for non-phosphorylated ERK 1/2 (1 : 500), to assess the total amount of ERK. The quantification of levels of phosphorylation, obtained after densitometric scanning of blots and normalization to non-phosphorylated ERK 1/2, was expressed as percentage compared with positive control (astrocytes treated with LPS), according to the following equation: % pERK 1/2 = (OD sample /OD positive control ) 9 100.
Statistical analysis
The number 'n' indicates the number of independent experiments performed with different cell cultures. Data from at least three different experiments, with each data point in an individual experiment representing triplicate measurements, were used for statistical analysis. Original data were converted into % values, as reported in the respective method sections, and mean AE SD was calculated.
Values were compared using one-way analysis of variance (ANOVA) followed by the Dunnett's Multiple Comparison post hoc test. The median toxic concentration (TC 50 ) was calculated for each drug from the plot of % cell viability versus log of drug concentration. Data were analyzed by the GraphPad Prism 5.0 (GraphPad Software Inc.).
Results
Effect of single antiretroviral drugs on astrocyte viability
In a first set of experiments, we evaluated the cytotoxicity of MVC, RAL and DRV in an in vitro system represented by primary cultures of rat astrocytes. For this purpose, purified astrocytes were treated with the antiretroviral drugs at concentrations ranging between 1 and 250 lM.
After 20 h of incubation at 37°C, 5% CO 2 the cells were photographed and subjected to the MTT test as described in the Method Section. The cell viability values, resulting from the MTT assay, were used to obtain, for each drug, a doseresponse curve of cell viability (Fig. 1) and to calculate the TC 50 values.
As shown in Table 1 , MVC was the less toxic drugs to astrocytes among those tested. In general, all the antiretroviral (ARV) drugs tested were toxic to astrocytes at concentrations higher than those measured in the plasma and CSF of HIV-positive subjects treated with ARVs.
Based on the results of the TC 50 and the viability curves reported in Fig. 1 , for our subsequent experiments concentrations of drugs that determined a cell survival higher than 60% were chosen as maximum non-toxic concentrations.
ROS production in astrocytes treated with ARV drugs
To elucidate the mechanisms of toxicity of the ARV drugs, we evaluated the production of ROS by astrocytes treated with MVC, RAL, or DRV. In particular, the intracellular ROS levels were measured in astrocytes treated with the individual drugs at doses that matched the drug concentrations detected in plasma and CSF of HIV-positive subjects as well as at the maximum non-toxic and at the TC 50 concentrations, as detected in vitro by the MTT assay (see Table 1 ). As shown in Fig. 2 , a statistically significant production of ROS, was observed for astrocytes treated with H 2 O 2 or with LPS (positive controls) as well as for astrocytes treated with the ARV drugs at the doses corresponding to TC 50 , compared to negative control (untreated astrocytes). Conversely, only a slight production of ROS, which was not statistically significant in comparison with the negative control, was observed after treatment with the drugs at the concentrations detected in plasma and CSF of HIV-infected patients as well as at the highest non-toxic concentrations.
The ARV drugs inhibit MMP-2 and MMP-9 levels in LPSactivated astrocytes To assess the effect of ARV drugs on levels of MMP-2 and MMP-9, astrocytes were activated with LPS, which is able to induce the expression of gelatinases (Gottschall and Deb 1996) , and simultaneously treated with the antiretroviral drugs at the maximum non-toxic concentrations and at concentrations that matched those measured in the plasma and CSF of HIV-infected individuals receiving cART (see Table 1 ).
As shown in the representative zymographic gels in Fig. 3 , two clear bands of digestion of 72 and 92 kDa were present on the dark background of the gel corresponding, respectively, to MMP-2 and MMP-9, identified by co-migration with MMP-2 and MMP-9 standards. Treatment of astrocytes with LPS led to an increase in the levels of MMP-2 and induced the synthesis of MMP-9. In contrast, treatment with MVC, RAL or DRV determined a dose-dependent reduction in the levels of both MMP-2 and MMP-9, which varied depending on the drug used. In particular, as shown in Fig. 3 , all the antiretroviral drugs tested exerted a statistically significant inhibition of MMP-2 and MMP-9 levels at the maximum non-toxic concentration. In addition, DRV inhibited levels of MMP-2 and MMP-9 at the concentration of 20 lM, which corresponds to the concentration detected in the plasma of HIV-infected patients.
The ARV drugs do not directly inhibit the activity of purified MMP-2 and MMP-9
In an in vitro assay, we also tested the ability of the studied ARVs to inhibit MMP-2 and MMP-9 activity. To do this, 0.35 lg of purified MMP-2 and 0.88 lg of purified MMP-9 were separated by gelatin zymography, then the zymogram was cut in lanes and each lane was incubated in developing buffer containing the single drugs at the maximum non-toxic concentrations. As a control, MMP-2 and MMP-9 were incubated in the presence of 1 mM of PA, an inhibitor of MMPs. The experiments showed that none of the ARVs tested exerted a direct inhibition on the enzymatic activity of MMP-2 and MMP-9. On the contrary, PA treatment completely blocked the activity of both MMP-2 and MMP-9 (Fig. 4) .
ARV drugs inhibit MMP-2 and MMP-9 gene expression in LPS-activated astrocytes
To determine whether the inhibition of MMP-2 and MMP-9 by the studied ARVs may result from the inhibition of mRNA, RT-PCR was performed. As shown in the representative gels in Fig. 5 the treatment of astrocytes with LPS led to an increased expression of MMP-2 and induced the synthesis of MMP-9.
In contrast, treatment with the individual ARV drugs resulted in the dose-dependent inhibition of MMP-2 and MMP-9 mRNA expression that varied depending on the drug used. Histograms in Fig. 5 represent the percentage of inhibition of MMP-2 and MMP-9 mRNA expression in comparison with the positive control. The quantitative analysis of the results, obtained after densitometric scanning of the gel, showed that all the ARV drugs tested, at the maximum non-toxic concentration, determined a statistically significant inhibition of MMP-9 and MMP-2 expression.
The studied ARV drugs at the concentration measured in plasma and CSF or HIV-infected patients did not show any statistically significant inhibition of MMP-2 and MMP-9, with the exception of DRV that inhibited the expression of MMP-2 and MMP-9 also at the concentration of 20 lM, Table 1 . Based on the viability curves, the concentrations of drugs that determined a cell viability above 60% were chosen as the maximum non-toxic concentrations. Solid lines indicate the TC 50 . Dashed lines indicate the maximum non-toxic concentrations.
which corresponds to the concentration detected in the plasma of HIV-infected patients.
ERK 1/2 is involved in the inhibition of MMP-9 expression by ARV drugs
To elucidate the molecular mechanism of inhibition of MMP-9 by the studied ARV drugs we tested their effect on the activation of ERK 1/2, which is the main signaling transduction pathway involved in the regulation of MMP-9 expression in LPS-activated astrocytes (Lee et al. 2003) . As shown in Fig 6, the treatment of astrocytes with LPS induced a statistically significant increase in the level of phosphorylation of ERK 1/2 (p-ERK) that was counteracted by pretreatment with the ARV drugs.
Effect of combination of ARV drugs on astrocyte cell viability In another set of experiments, astrocytes were activated with LPS and treated with the ARV drugs, used in different combinations as reported in Table 2 .
In particular, pool 1 contained the ARV drugs at the concentration of 25 lM, which represented the maximum non-toxic dose of the drugs used in combination (data not shown); pools 2 and 3 contained the drugs at the doses found, respectively, in plasma and CSF of HIV-positive subjects under treatment. The histograms in Fig. 7 show the results of the cell viability test of astrocytes obtained after treatment with the various pools of drugs. As can be seen, no pool appeared to be toxic to the cells. The observation of the cells under an optical microscope confirmed that both the morphology and the number of cells treated with the different pools appear to be similar to that of control cells.
Synergistic inhibition of MMP-2 and MMP-9 levels and expression by ARV drugs in LPS-activated astrocytes As shown in Fig. 8 , only pools 1 and 2, containing the ARV drugs at the maximum non-toxic concentrations for astrocytes and at the concentrations detected in plasma of HIVinfected individuals, respectively, were able to significantly inhibit levels and expression of MMP-2 and MMP-9.
Pool 3, containing drugs at concentrations similar to those detected in the CSF of HIV-infected individuals, determined a reduction in the levels of MMPs that, however, did not result to be statistically significant.
A comparison of the inhibitory effect exerted by the single drugs and the different pools on MMP-2 and MMP-9 levels is shown in Fig. 9 . As can be seen, all the pools containing the drugs at the maximum non-toxic concentrations and at the plasma concentrations, exhibited a synergistic inhibitory effect against MMP-2 and MMP-9, compared to the individual drugs used at the same concentrations.
Discussion
Despite the success of cART in controlling viral replication and disease progression, HIV-associated neurological disorders remain a major clinical problem (Clifford 2008) . In fact, although ART has resulted in a decrease in the incidence of the most severe neurological forms, such as HAD, less severe cognitive disorders, often asymptomatic, still affect many patients (Heaton et al. 2010) . The persistence of these neurological manifestations may be attributable not only to the evidence that HIV subjects live longer (Robertson et al. 2007; Heaton et al. 2011) , but also to the reduced CNS penetration of ARV drugs through the BBB with a reduced effectiveness in controlling HIV reservoir (Valcour et al. 2011) . Moreover, also the neurotoxicity of ARV drugs might contribute to the neurological damage.
In this respect, although the toxicity of many antiretroviral drugs, such as the non-nucleoside transcriptase inhibitor efavirenz, is well documented at systemic level and in the nervous system (Chen et al. 2013; Apostolova et al. 2015; Ma et al. 2016 ) the toxic effect of second generation ARVs to neurons and glial cells is not well elucidated particularly at concentrations that provide effective viral suppression. In this study, we evaluated the toxicity of three antiretroviral drugs used in cART regimens on astrocytes and we determined the maximum non-toxic doses of the different drugs. In particular, we used three drugs belonging to different classes, which reduce the HIV viral load with different mechanisms of action.
Darunavir (DRV), an inhibitor of HIV protease, prevents the maturation of new viral particles; maraviroc (MVC), an inhibitor of entry, counteracts the entry of the virus into the 'host cell' by C-C chemokine receptor type inhibition, finally, raltegravir (RAL) acts on the enzyme integrase preventing the insertion of viral DNA into the human genome. In our experiments, we treated astrocytes with increasing doses of the drugs and the toxicity was evaluated by the MTT cell viability test, widely used for this purpose (Robertson et al. 2012) .
It should be noted that the toxic concentration of ARVs, found by us on astrocytes, resulted to be comparable to those found by Robertson et al. (2012) on primary cultures of rat neurons.
It is noteworthy that the results of our study showed that all the drugs used were toxic in vitro to astrocytes at concentrations higher than those measured in the CSF and plasma of HIV-infected subjects under treatment (Yilmaz et al. 2009a,b,c; Robertson et al. 2012) , suggesting that they are not harmful to brain cells at the doses currently administered.
Several evidences indicate that antiretroviral drugs can induce neurotoxicity through an alteration in the brain redox status (Akay et al. 2014) , therefore, in this study, we evaluated ROS production in ARV-treated astrocytes. Our results indicated that only drugs used at the TC 50 concentration significantly induced ROS production indicating that the alteration of cellular redox state could be implicated in antiretroviral toxicity. Fig. 4 In-gel inhibition of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) activity by antiretroviral drugs. MMP-2 and MMP-9 standard were applied to gelatin-zymography. After the electrophoretic run in sodium dodecyl sulfate, gels were cut in lanes and each lane was washed with Triton X-100 and incubated overnight in the incubation medium (50 mM Tris; 1% Triton-X-100; 10 mM CaCl 2 ; 0.2% NaN3; pH 7.5) in the absence or in the presence of MVC (175 lM), RAL (50 lM), or DRV (50 lM). 1,10 phenantrolin (PA) was used as a positive control. Staining and destaining of the gels revealed that only PA was able to inhibit both MMP-2 and MMP-9. The second objective of our study was to test the effect of MVC, RAL and DRV on the release of MMP-2 and MMP-9 by astrocytes. The rationale for this study stems from the observation that MMPs, and in particular gelatinases A (MMP-2) and B (MMP-9), have been identified as important pathogenetic factors in HIV-infection and HIV-related neurological syndromes (Liuzzi et al. 2000; Mastroianni and Liuzzi 2007) . The involvement of MMPs in these diseases derives from the ability of these enzymes to degrade components of the extracellular matrix thus contributing to the spreading of virus in tissues and, more specifically about the CNS, to BBB degradation and demyelination. In addition, it was demonstrated the ability of some antiretroviral drugs to inhibit the expression of MMP-9 both in glial cells in vitro and in peripheral blood mononuclear cells of HIV-positive patients (Liuzzi et al. 2004a; Latronico et al. 2007; Gramegna et al. 2011) .
The mechanisms by which MMPs are activated in HIVinfection are not yet clear. It is known, however, that CD4 + depletion is accompanied to a marked and persistent immune activation that paradoxically accelerates viral replication, CD4
+ depletion and the progression of the disease. The chronic immune activation is manifested by increased plasma levels of chemokines and pro-inflammatory cytokines, which may be responsible for MMP overexpression . In this respect, several lines of evidence suggest that the main mechanism of neurological disorders associated with HIV is indirect, through the release of pro-inflammatory cytokines, ROS and NO by glial cells activated in response to residual viral replication (Lisi et al. 2014) . Chronic inflammation, leading to viral infection, could trigger a chain reaction: the release of inflammatory mediators would activate MMPs, which, by degrading the components of the basal lamina, would facilitate the migration and spreading of virus in brain tissue. Peripheral monocytes and macrophages provide a source of virus that can then infect glial cells which represent a viral reservoir difficult to reach by both drugs and immune system. Therefore, inhibition of the expression of MMPs in activated glial cells may be a useful mechanism to counteract the chronic inflammation of the CNS and the subsequent development of HIV-related neurological diseases.
In this study, we used an experimental model represented by LPS-activated astrocytes and demonstrated the ability of MVC, RAL, and DRV to inhibit MMP levels at the highest non-toxic concentration for astrocytes.
The reason to use astrocytes stimulated with LPS rather than with any HIV fragments or with HIV itself derives from the observation that this experimental model, already used to evaluate the effect of other antiretroviral drugs on astrocytes (Liuzzi et al. 2004a) , best describes the indirect activation of astrocytes related to residual immune activation, present also in patients with suppressed viral load following cART treatment. In addition, HIV-associated systemic immune activation is linked to increased circulating levels of LPS, as a consequence of microbial translocation from the damaged gastrointestinal tract. Since translocated LPS is involved in the up-regulation of MMP secretion by innate immune cells, such as monocytes/macrophages, dendritic cells, and microglia, in our opinion the treatment of astrocytes with LPS, seems to be more than justified. In general, the concentrations of these drugs that, in our in vitro experiments, were inhibitory against MMP-2 and MMP-9 in astrocytes are substantially higher than those measured for such drugs in the CSF of HIV-positive subjects.
This finding could indicate that the doses of drugs that reach the CNS are not sufficient to exert their inhibitory effect on MMPs. However, it is conceivable that in neuropathological situations, common to HIV-related neurological diseases, BBB is damaged, so, as suggested by Gissl en and Hagberg (2001) , the concentrations of ARVs that actually reach the Table 2 . After 20 h of treatment equal amounts of cell culture supernatants were analyzed by gelatin zymography. Cells were subjected to total RNA extraction and analyzed by RT-PCR. Histograms represent the percentage of inhibition of MMP-2 and MMP-9 levels (a) and mRNA expression (b) in comparison with the positive control (LPS-activated astrocytes) which was set at 100%, calculated after scanning densitometry and computerized analysis of gels. Data represent means AE SD of n = 3 experiments performed on different cell populations. Asterisks represent values statistically different from positive control (one-way ANOVA followed by the Dunnett's Multiple Comparison post hoc test; *p < 0.05; **p < 0.01).
brain parenchyma may be higher than those measured in the CSF ,i.e. closer to plasma concentrations. In this regard, it should be noted that at least for DRV, the inhibitory concentrations towards MMP-2 and MMP-9 are comparable with those detected for this drug in plasma. Therefore, the effectiveness of DRV on in vivo MMP inhibition may be higher in course of severe neurological disorders, such as HAD, in which a damaged BBB has been shown (Anesten et al. 2016) .
Although at present, in clinical practice, first line antiretroviral therapy includes always a triple combination, some simplification strategies are based on mono or dual therapy. In this respect, some simplified strategies based on DRV dual therapy or monotherapy gave promising results especially for patients that are long term HIV suppressed with high CD4 nadir (Gagliardini et al. 2014; Antinori et al. 2015) . Our data, therefore, could suggest a more potent effect of DRV alone that could support the use of monotherapy with this protease inhibitor in virologically suppressed patients.
An important result of this study is the demonstration that the ARV drugs used in combination exhibited a synergistic effect resulting in a higher inhibition of MMP levels and expression compared to the individual drugs used at higher concentrations. This finding suggests that the best therapeutic strategy to block MMPs consists in the use of combined therapies with drugs belonging to different classes, which offer the advantage of reducing the doses of drug, and thus the possible toxicity at cerebral level, retaining an effective inhibition of MMPs.
The mechanisms by which the antiretroviral drugs are able to interfere with the production of MMPs in astrocytes are currently unknown. In our experiments, we demonstrated that the studied antiretroviral drugs did not directly inhibit the activity of MMP-2 and MMP-9 but were able to significantly inhibit the gene expression of MMP-2 and MMP-9 suggesting that they act at transcriptional level. To verify this hypothesis, we studied the effect of these drugs on the signal transduction pathways involved in the activation of MMP-9 gene. In particular, we focused our attention on ERK 1/2 MAPKs, which is the main pathway involved in the regulation of MMP-9 expression in LPSactivated astrocytes (Lee et al. 2003) . We observed that MVC, RAL, and DRV are able to reduce significantly the levels of p-ERK 1/2 in LPS-treated astrocytes, indicating that the ability of the studied ARVs to counteract the overexpression of MMP-9 is related to the modulation of ERK signaling pathway.
In conclusion, it is important to note that although this in vitro study cannot provide clear answers regarding the potential impact of long-term exposure to ARV drugs or potential drug interactions in vivo that may influence neurotoxicity, it provides important information to avoid the potential risks associated with the interaction of antiretrovirals with resident cells of the CNS. Furthermore, the results of MMP inhibition by the drugs studied add useful information for the development of novel therapeutic strategies that, by reducing the risk of neurotoxicity of antiretroviral drugs, could block the action of important pathogenetic factors of HIV-related neurological diseases.
